Primary Peritoneal
| Treatment Stage | Protocol Title | ClinicalTrials.Gov Link | Penn Research Coordinator | Am I Eligible? |
|---|---|---|---|---|
| Stage II-IV Newly Diagnosed | GY019: A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum | Eligibility Criteria | ||
| Recurrent | GOG 3096: A Phase 2/3, Multicenter, Randomized Study of Raludotatug Deruxtecan (R-DXd), a CDH6-directed Antibody-drug Conjugate, in Subjects with Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer |
NCT06161025 | Kristina Powell | Eligibility Criteria |
| Recurrent | GOG 3066: A Phase 2 Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT04814108 | Kristina Powell | Eligibility Criteria |
| Recurrent | STAR-101: A Phase 1 Study of SynKIR-110, Autologous T cells Transduced with Mesothelin KIR-CAR, in Subjects with Mesothelin-Expressing Advanced Ovarian Cancer, Cholangiocarcinoma, or Mesothelioma | NCT05568680 | Andrea Standish, RN | Eligibility Criteria |
| Recurrent | NP-G2-044-P2-01: NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies | NCT05023486 | Brianna Aguilar | |
| Recurrent | NRG-GY031: A Phase 1B Study of Combination ATR (M1774) and BET Inhibition (ZEN003694) to Exploit ARID1A Loss in Recurrent Ovarian and Endometrial Cancer | NCT05950464 | Andrea Standish, RN |
ON HOLD |
| Recurrent | Phase 1/2 Study of REGN5668 (MUC16 X CD28, A Costimulatory Bispecific) Administered in Combination with Cemiplimab or REGN4018 (MUC16 X CD3) | NCT04590326 | Katie Hayes, RN | Eligibility Criteria |
| Recurrent | A Phase 1, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGN151 (anti-FRα antibody-drug conjugate) in Adult Patients with Recurrent Gynecological Cancers | NCT05527184 | Kristina Powell | Eligibility Criteria |
| Recurrent | Phase 1/2 study evaluating genetically modified autologous T cells expressing a T-cell receptor recognizing a cancer/germline antigen as monotherapy or in combination with nivolumab in patients with recurrent and/or refractory solid tumors | NCT03686124 | Katie Hayes, RN | |
| Recurrent | GOG 3115: A Single Arm, Phase 2 Study of Neoadjuvant Carboplatin and Mirvetuximab Soravtansine in Subjects with Folate Receptor Alpha Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer | NCT04606914 | Brianna Aguilar | Eligibility Criteria |
| Recurrent | GOG 3121: Randomized Phase 2/3 Trial of NP-G2-044 Combined with PLD for Treatment of Platinum-Resistant Ovarian Cancer | NCT07109414 | Brianna Aguilar | Eligibility Criteria |
| Recurrent | Study of NMS-03305293, a Non-Trapping PARP1-Specific PARP Inhibitor in Relapsed Ovarian Cancer | NCT06930755 | Katie Elkins | Eligibility Criteria |
| Recurrent (Clear Cell) | Phase 2 Study of Senaparib in Combination with Temozolomide in ARID1A mutation associated Ovarian Cancer | NCT06617923 | Andrea Standish, RN | Eligibility Criteria |
| Maintenance | UPROAR: A phase II evaluation of maintenance therapy combination Mirvetuximab Soravtansine and Olaparib in Recurrent Platinum Sensitive Ovarian, Peritoneal, and Fallopian Tube Cancer | NCT05887609 | Kristina Powell | Eligibility Criteria |
| Maintenance | NRG-GY036: A Phase III Trial of One Vs Two Years of Maintenance Olaparib, with or without Bevacizumab, in Patients with BRCA1/2 Mutated or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Response to First Line Platinum Based Chemotherapy | NCT06580314 | Brianna Aguilar | Eligibility Criteria |